News & Press Releases

Newsroom

Keep up with the latest news from Anocca

Press releases

Anocca utser Martin Welschof till styrelsen

SÖDERTÄLJE, 13 februari 2024 – Anocca AB, ett ledande TCR-T[1]-cellterapiföretag, tillkännagav idag utnämningen av Martin Welschof till sin styrelse. Martin Welschof är för närvarande vd för BioInvent International AB, ett börsnoterat cancerimmunterapiföretag i...

Anocca Appoints Martin Welschof to Board of Directors

SÖDERTÄLJE, SWEDEN, 13 February 2024 – Anocca AB, a leading TCR-T[1] cell therapy company, today announced the appointment of Martin Welschof to its Board of Directors. Martin Welschof is currently CEO of BioInvent International AB, a listed clinical-stage cancer...

Anocca utser Martin Welschof till styrelsen

SÖDERTÄLJE, 13 februari 2024 – Anocca AB, ett ledande TCR-T[1]-cellterapiföretag, tillkännagav idag utnämningen av Martin Welschof till sin styrelse. Martin Welschof är för närvarande vd för BioInvent International AB, ett börsnoterat cancerimmunterapiföretag i...

Anocca Appoints Martin Welschof to Board of Directors

SÖDERTÄLJE, SWEDEN, 13 February 2024 – Anocca AB, a leading TCR-T[1] cell therapy company, today announced the appointment of Martin Welschof to its Board of Directors. Martin Welschof is currently CEO of BioInvent International AB, a listed clinical-stage cancer...

Anocca in the news

Anocca: Standardizing TCR cell therapy design

Originally published in BioCentury. Anocca is using engineered human cells to recapitulate the T cell immune system ex vivo, eliminating the person-to-person variability in working with primary T cells from patients, to create standardized, scalable TCR-modified T...

Reports & Regulatory press releases